Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral...

MolecularMD is acquired by ICON PORTLAND, Ore. and CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- MolecularMD Corporation, a  molecular diagnostic specialty laboratory that enables the development and commercialisation of...

MolecularMD to Implement Promega’s Microsatellite Instability (MSI) Technology for Immuno-Oncology Applications PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- MolecularMD announces that it has now become a Preferred Provider of Promega’s Microsatellite Instability (MSI) v1.2 Analysis...

MolecularMD Announces Partnership with Indica Labs to Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services PORTLAND, Ore. and CAMBRIDGE, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- MolecularMD, a provider of molecular and tissue-based clinical trial assays and diagnostics for oncology based drug...